Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: Results of the European compassionate-use programme

Heidenreich A., Bracarda S., Mason M., Ozen H., Sengelov L., Van Oort I., ...Daha Fazla

EUROPEAN JOURNAL OF CANCER, cilt.50, sa.6, ss.1090-1099, 2014 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 50 Sayı: 6
  • Basım Tarihi: 2014
  • Doi Numarası: 10.1016/j.ejca.2014.01.006
  • Dergi Adı: EUROPEAN JOURNAL OF CANCER
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1090-1099
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Background: Cabazitaxel/prednisone has been shown to prolong survival versus mitoxantrone/prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or after docetaxel. Subsequently, compassionate-use programmes (CUPs) and expanded-access programmes (EAPs) were established worldwide, allowing access to cabazitaxel before its commercial availability. Preliminary results of the European CUP/EAP, focusing on the elderly population (aged >= 70 years), are reported.